Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs

被引:22
|
作者
Finlay, Andrea K. [1 ,2 ]
Ellerbe, Laura S. [1 ]
Wong, Jessie J. [1 ,3 ]
Timko, Christine [1 ,3 ]
Rubinsky, Anna D. [4 ,5 ]
Gupta, Shalini [1 ]
Bowe, Thomas R. [1 ]
Burden, Jennifer L. [6 ]
Harris, Alex H. S. [1 ,7 ]
机构
[1] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[2] Dept Vet Affairs, Natl Ctr Homelessness Vet, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Menlo Pk, CA 94025 USA
[4] Univ Calif San Francisco, Kidney Hlth Res Collaborat, 500 Parnassus Ave, San Francisco, CA 94143 USA
[5] San Francisco VA Med Ctr, 500 Parnassus Ave, San Francisco, CA 94143 USA
[6] Vet Hlth Adm, Dept Vet Affairs, 1970 Roanoke Blvd,116A, Salem, VA 24153 USA
[7] Stanford Univ, Sch Med, Dept Surg, Alway Bldg,Room M121,300 Pasteur Dr, Stanford, CA 94305 USA
关键词
Alcohol-related disorders; Alcohol dependence; Pharmacotherapy; Veterans; Residential treatment; MENTAL-HEALTH; VETERANS; IMPLEMENTATION; DEPENDENCE; SETTINGS;
D O I
10.1016/j.jsat.2017.03.005
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care. The Department of Veterans Affairs (VA) delivers intensive, highly structured addiction and psychosocial treatment through residential programs. Despite the evidence supporting pharmacotherapy among the effective treatments for AUD, receipt of these medications (e.g., naltrexone, acamprosate) among patients in residential treatment programs varies widely. In order to better understand this variation, the current study examined barriers and facilitators to use of pharmacotherapy for AUD among patients in VA residential treatment programs. Semi-structured qualitative interviews with residential program management and staff were conducted and the Consolidated Framework for Implementation Research was used to guide coding and analysis of interview transcripts. Barriers to use of pharmacotherapy for AUD included cultural norms or philosophy against prescribing, lack of access to willing prescribers, lack of interest from leadership, and perceived lack of patient interest or need. Facilitators included cultural norms of openness or active promotion of pharmacotherapy; education for patients, program staff and prescribers; having prescribers on staff, and care coordination within residential treatment and with other clinic settings in and outside VA. Developing and testing improvement strategies to increase care coordination and consistent support from leadership may also yield increases in the use of pharmacotherapy for AUD among residential patients. Published by Elsevier Inc
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [31] Alcohol use disorder pharmacotherapy and treatment in primary care (ADaPT-PC) trial: Impact on identified barriers to implementation
    Hagedorn, Hildi J.
    Wisdom, Jennifer P.
    Gerould, Heather
    Pinsker, Erika
    Brown, Randall
    Dawes, Michael
    Dieperink, Eric
    Myrick, Donald Hugh
    Oliva, Elizabeth M.
    Wagner, Todd H.
    Harris, Alex H. S.
    SUBSTANCE ABUSE, 2022, 43 (01) : 1043 - 1050
  • [32] Barriers and Facilitators to Expanding Buprenorphine Treatment for Opioid Use Disorder in Jail Settings
    Kelsch, Jordan
    McGladrey, Margaret
    Oser, Carrie
    Booty, Marisa
    Fanucchi, Laura
    Walsh, Sharon
    Lofwall, Michelle
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [33] ADOPTION OF ALCOHOL USE DISORDER PHARMACOTHERAPY BY PROVIDERS OF BUPRENORPHINE TREATMENT FOR OPIOID USE DISORDER IN THE UNITED STATES
    Knudsen, H. K.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 : 63A - 63A
  • [34] Facilitators and barriers of alcohol goals for Latinx men hospitalized with alcohol use disorder seen by an Addiction Consult Team
    Carson, Mariam S.
    Haro-Ramos, Alein Y.
    Lopez-Solano, Naomi
    Fernandez, Carla
    Cummins, Marcus
    Fernandez, Alicia
    Defries, Triveni
    Martin, Marlene
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [35] Genetics of Alcohol Use Disorder and Precision Pharmacotherapy
    Kranzler, Henry
    Feinn, Richard
    Xu, Heng
    Witkiewitz, Katie
    Zhou, Hang
    Gelernter, Joel
    Kember, Rachel
    BIOLOGICAL PSYCHIATRY, 2023, 93 (09) : S29 - S29
  • [36] Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
    Belnap, Malia A.
    Mcmanus, Kaitlin R.
    Grodin, Erica N.
    Ray, Lara A.
    PHARMACEUTICAL MEDICINE, 2024, 38 (04) : 291 - 302
  • [37] Diagnosis and Pharmacotherapy of Alcohol Use Disorder A Review
    Kranzler, Henry R.
    Soyka, Michael
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (08): : 815 - 824
  • [38] Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use
    Hollander, Mara A. G.
    Chang, Chung-Chou H.
    Douaihy, Antoine B.
    Hulsey, Eric
    Donohue, Julie M.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 227
  • [39] Improving access to alcohol use disorder pharmacotherapy and treatment in primary care settings
    Hildi Hagedorn
    Alex Sox-Harris
    Jennifer Wisdom
    Donald Hugh Myrick
    Michael Dawes
    Randall Brown
    Elizabeth Oliva
    Implementation Science, 10 (Suppl 1)
  • [40] IMPULSIVITY PREDICTS READMISSION TO RESIDENTIAL TREATMENT FOR ADOLESCENTS WITH ALCOHOL USE DISORDER
    Stein, E. R.
    Rieselbach, M.
    McWhinnie, C. M.
    Silveri, M. M.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2017, 41 : 97A - 97A